Catalent, Novo Nordisk

Novo completes $16.5bn takeover of Catalent
Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.
Novo Holdings completes $16.5 billion takeover of Catalent
Novo Holdings has completed its $16.5 billion acquisition of Catalent, the contract drug manufacturer said on Wednesday, days after the companies disclosed that all regulatory conditions to close the deal were fulfilled.
Novo Holdings says its acquisition of Catalent is complete.
Novo Nordisk plans to buy from the holding company three sites — Brussels; Anagni, Italy; and Bloomington — for $11.7 billion.
Novo Holdings set to close $16.5B Catalent buy in 'coming days' after deal clears antitrust hurdles
After clearing all regulatory hurdles associated with its proposed buyout of CDMO Catalent, Novo Holdings is nearly ready to unwrap its $16.5 billion present just in time for the holidays.
Novo Holdings closes $16.5 billion buyout of contract manufacturer Catalent
Novo Holdings, the controlling shareholder of Novo Nordisk, on Wednesday sealed its $16.5 billion deal for Catalent, as the Danish drugmaker looks to boost supplies of its widely popular weight-loss drug Wegovy.
Catalent Acquired by Novo Holdings in $16.5 Billion Deal
The latest announcement is out from Catalent ( (CTLT) ).
Novo Holdings says its acquisition of Catalent will be complete 'in the coming days'
Indications are that Novo will be investing in both the plant and the community,” an Indiana University professor said.
MM&M3d
Novo Holdings’ $16.5B deal for Catalent clears last regulatory hurdle
Novo Holdings is on track to acquire Catalent, a global contract development and manufacturing organization, in a $16.5 ...
STAT3d
Pharmalittle: We’re reading about Novo Holdings proceeding with Catalent deal, Sanofi threatened with sanctions, and more
Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge ...
Novo Nordisk Completes Strategic Acquisition to Enhance Manufacturing Capacity
Novo Nordisk ( (NVO) ) has provided an announcement.
Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent
Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) announced plans to invest approximately $1.20 billion (8.5 billion ...
Indiana Daily Student4d
Novo’s takeover of Catalent set to proceed after FTC declines to challenge deal
Novo Holdings will proceed with its $16.5 billion acquisition of Catalent, the companies announced Saturday, after the ...
Seeking Alpha5d
Novo Nordisk says Catalent buyout to close soon as regulatory conditions met
Novo Nordisk (NVO) announced Saturday that its pending acquisition of three Catalent (NYSE:CTLT) production sites is expected to close within days as its parent entity satisfied all regulatory ...
devdiscourse3d
Healthcare Innovations: Novo Nordisk's Strategic Moves and Emerging Drug Trends
Novo Nordisk is investing $1.2 billion in a rare disease drugs facility in Denmark, weight-loss drugs surge American ...